Clause,Label 1,Label 1-Answer,Label 2,Label 2-Answer
Development Agreement,Document Name,Development Agreement
"CNS Pharmaceuticals, Inc., ""CNS"", WPD Pharmaceuticals, ""WPD"", CNS and WPD are sometimes referred to herein individually as a ""Party"" and collectively as the ""Parties."", ""WPD"", WPD Pharmaceuticals, ""CNS"", CNS Pharmaceuticals, Inc.",Parties,"CNS Pharmaceuticals, Inc. (""CNS""); WPD Pharmaceuticals (""WPD"")(""Party"" and collectively as the ""Parties"")"
"March 20, 2020",Agreement Date,03/20/2020,Effective Date,03/20/2020
"The term of this Agreement will commence on the Effective Date and remain in full force and effect until the expiration of the Sublicense Agreement, unless earlier termination by pursuant to the terms of this Agreement (""Term"").",Expiration Date,(None entered)
"This Agreement will be governed by, construed and enforced in accordance with the laws of the State of Texas.",Governing Law,Texas
"""Development Fee"" means 50% of the Net Sales for any Development Products in the Development Territory.",Revenue/Profit Sharing,Yes
The first Development Fees payment shall be due forty-five days after the end of the Calendar Quarter in which the first Sale of a Development Product took place.,Revenue/Profit Sharing,Yes
"Thereafter, WPD shall furnish to CNS Development Fees no later than forty-five days after the end of each Calendar Quarter for the Sale of Development Products through the end of such Calendar Quarter and shall further furnish CNS with a written statement setting forth an accounting showing the calculation of the Development Fees.",Revenue/Profit Sharing,Yes
"WPD shall, and shall cause its respective affiliates, to permit CNS and its respective designated representatives, at reasonable times and upon reasonable prior notice to such parties, to review the books and records of WPD and any of its affiliates and to discuss the affairs, finances and condition of such party and any of its affiliates with the officers of such entities and any of their affiliates in relation to their compliance with this section, as applicable.",Audit Rights,Yes
